Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Medtronic's Diabetes Business Prepares for Spinoff, Launches New Products

Medtronic's diabetes business is gearing up for a significant transformation as it prepares to spin off into a standalone company, MiniMed, while simultaneously launching new products and expanding partnerships in the competitive diabetes care market.

NoahAI News9/25/2025

Moderna Opens UK Vaccine Facility Amid Industry Backlash Against British Life Sciences Policies

Moderna has officially inaugurated its Harwell vaccine production facility in the UK, reaffirming its commitment to the country even as other pharmaceutical giants voice concerns about Britain's life sciences landscape. The new site, dubbed the Moderna Innovation and Technology Centre, marks a significant milestone in the company's ongoing partnership with the UK government.

NoahAI News9/25/2025

Eli Lilly Halts Phase 2b Obesity Trial for Strategic Reasons

Eli Lilly has unexpectedly withdrawn a phase 2b obesity trial before patient enrollment began, citing "strategic business reasons." The study was designed to evaluate bimagrumab, an asset acquired through Lilly's $1.9 billion Versanis acquisition, both as a standalone treatment and in combination with the company's blockbuster GLP-1/GIP drug tirzepatide.

NoahAI News9/25/2025

Cancer Pain Management: Challenges and Progress in Pharmaceutical Development

The pharmaceutical industry faces ongoing challenges in developing effective treatments for cancer-related pain, even as patients live longer with the disease. Despite advances in cancer therapies, pain management options have not kept pace, leaving millions suffering from debilitating symptoms.

NoahAI News9/25/2025

Heidelberg Pharma Announces Major Restructuring Following FDA Setback

Heidelberg Pharma, a German biotech company, has announced a significant restructuring plan following a regulatory setback that has delayed a crucial milestone payment. The company will reduce its workforce by 75% and narrow its research focus in an effort to extend its cash runway into mid-2026.

NoahAI News9/25/2025

Medtronic Expands AI and Robotics Hub, While Virtuoso Surgical Receives FDA Breakthrough Designation

Medtronic, a leading medical technology company, has announced a significant expansion of its London office, establishing it as the company's largest global digital center for artificial intelligence (AI) and robotics in surgery. Meanwhile, Virtuoso Surgical has received FDA breakthrough device designation for its robotic system designed for bladder lesion removal.

NoahAI News9/25/2025

Talent Acquisition Leaders Shift Focus to Internal Mobility and Workforce Development

In a rapidly evolving pharmaceutical landscape, talent acquisition leaders at major companies are redefining their approach to recruitment and workforce management. This shift comes as a response to industry-wide restructuring and the need for increased business agility. Companies like Pfizer and Bayer are at the forefront of this transformation, leveraging new technologies and strategies to support internal mobility, upskilling, and reskilling of their existing workforce.

NoahAI News9/25/2025

Acadia Pharmaceuticals Halts Development of Prader-Willi Syndrome Drug After Phase III Failure

Acadia Pharmaceuticals has announced the discontinuation of its investigational treatment for hyperphagia in Prader-Willi syndrome (PWS) following disappointing results from a late-stage clinical trial. The decision marks a significant setback in the development of potential therapies for this rare neurological condition.

NoahAI News9/25/2025

Sanofi Injects $625M into Venture Arm, Bolstering Early-Stage Biotech Investments

Sanofi has announced a significant boost to its corporate venture capital arm, Sanofi Ventures, with a $625 million cash infusion. This move underscores the pharmaceutical giant's commitment to fostering innovation in the biotech and digital health sectors, particularly in areas aligned with its strategic focus.

NoahAI News9/25/2025

UniQure's Huntington's Gene Therapy Shows Promising Results, Paving Way for Potential Approval

UniQure has reported groundbreaking results from its Phase 1/2 trial of AMT-130, a gene therapy for Huntington's disease, demonstrating a 75% slowing of disease progression after three years. This development positions the company to potentially launch the first genetic treatment for this devastating neurodegenerative disorder.

NoahAI News9/25/2025

Fujifilm Biotechnologies Unveils $3.2B Antibody Facility in North Carolina, Ushering in New Era of Biomanufacturing

Fujifilm Biotechnologies has officially opened its highly anticipated $3.2 billion cell culture facility in Holly Springs, North Carolina, marking a significant milestone in the company's expansion efforts and solidifying its position as a major player in the biopharmaceutical manufacturing landscape.

NoahAI News9/25/2025

FDA Rejects Two Spinal Muscular Atrophy Therapies, Citing Manufacturing Concerns

The U.S. Food and Drug Administration (FDA) has dealt a double blow to the spinal muscular atrophy (SMA) treatment landscape, rejecting two therapies on the same day due to manufacturing issues. Biogen's high-dose formulation of Spinraza and Scholar Rock's apitegromab both received complete response letters from the regulatory agency, highlighting the importance of robust manufacturing processes in drug development.

NoahAI News9/25/2025

«1...47 48 49...67 »